CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-15). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2657 · Search date 2026-08-15 · Methodology v0.7

Oral cryotherapy,
does it really help with Reduced WHO grade 3-4 severe oral mucositis?

30-Second Summary
C
Evidence Grade C · 56 · Safety caution
Severe mucositis fell under one specific conditioning regimen, but evidence comes from one small trial
Ice can cause cold discomfort, dental sensitivity, nausea, and swallowing difficulty. Patients with impaired consciousness, swallowing problems, or aspiration risk should not use it without transplant-team supervision.
What the
research shows
The grade is C with 56 points. A four-arm trial randomized 160 patients and assessed 145. Severe oral mucositis occurred in 13.2% with ice throughout drug infusion versus 39.4% with usual oral care; the A-versus-D comparison had P=.011. The roughly 26-point absolute difference, an NNT near 4, was large, but a single sub-200-person center with unverified concealment, registration, and masking remains C evidence.
What the
ads claim
The trial does not show that ice prevents every form of cancer-treatment mucositis. It tested schedules tied to specific conditioning-drug infusions.
*

Useful facts when choosing a product

  • Four schedules were compared: whole infusion, second half, 15 minutes twice daily, and usual oral care.
  • Severe mucositis was about 13.2% with whole-infusion cooling and 39.4% with usual care.
  • No registration number was verified, and 145 of 160 randomized patients entered mucositis assessment.
Gap Measurement · Verdict 2657 · C 56
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 2020 single-center four-arm randomized trial by Lu Y, Zhu X, Ma Q, Wang J, Jiang P, Teng S, Zhou L, Wu D, and Wang H enrolled 160 and assessed 145 patients through post-transplant day 15: 38, 36, 36, and 35 per arm. Cooling covered the full infusion, the second half, twice daily for 15 minutes, or was omitted under usual oral care. Severe mucositis was about 13.2%, 19.4%, 41.7%, and 39.4%; A versus D P=.011, B versus D P=.068, and C versus D P=.848. Funding from the Suzhou Municipal Science and Technology Bureau, SYSD2016083, was verified; no trial registration number was verified.

02

Why this is classified as C (56)

A large publicly funded difference in a clinical complication was limited by one small center and incomplete reporting of allocation, registration, and outcome hierarchy, giving C with 56 points.

Counterpoint. Cold intolerance, dental sensitivity, nausea, and swallowing difficulty may make prolonged cryotherapy unsuitable for some patients.

Rejudgment record. Cross-check applied — Cross-checked 160 randomized, 145 assessed, severe-mucositis rates and P values across four schedules, and public funding against the original bibliographic record and accessible original-study summaries

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Prevention of severe mucositis with whole-infusion cryotherapyCRates were about 13.2% versus 39.4%, P=.011.
Cryotherapy for 15 minutes twice dailyDIt did not differ from usual care, P=.848.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Lu Y, Zhu X, Ma Q, Wang J, Jiang P, Teng S, Zhou L, Wu D, Wang H. 2020Single-center four-arm prospective randomized trial35Suzhou Municipal Science and Technology Bureau, SYSD2016083Severe oral mucositis and duration through post-transplant day 15Severe mucositis about 13.2%, 19.4%, 41.7%, and 39.4%; A versus D P=.011Large publicly funded event-rate difference from one small trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-15).

Lu Y, Zhu X, Ma Q, Wang J, Jiang P, Teng S, Zhou L, Wu D, Wang H. Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study. Support Care Cancer. 2020;28(4):1747-1754. PMID: 31302767. DOI: 10.1007/s00520-019-04966-z. Trial registration: not verified.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-15 · Corrections: none

Cite this verdict

Oral cryotherapy x severe mucositis during allogeneic HSCT Evidence Grade C card
[Chamgap] Oral cryotherapy x severe mucositis during allogeneic HSCT — Evidence Grade C·56. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/oral-cryotherapy-allogeneic-hsct-severe-mucositis/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.